Latest / Decera Clinical Education Oncology Podcast
Incorporating Immune Checkpoint Inhibitors Into Practice for Advanced Urothelial Cancer: Expert Perspectives From the Netherlands and the United Kingdom
In this episode, Thomas Powles, MBBS, MRCP, MD, and Michiel van der Heijden, MD, PhD, discuss key data on immune checkpoint inhibitors for urothelial carcinoma informing their clinical practice in the United Kingdom and the Netherlands. Topics include:
Data from registrational trials in the European Union for pembrolizumab and atezolizumab in the first-line/second-line settings
Utility of PD-L1 and tumor mutational burden as biomarkers for immune checkpoint inhibitor–based therapy
Results from the JAVELIN trial on avelumab maintenance after chemotherapy
When to consider first-line treatment…
The skinny
The skinny isn't ready yet — notes appear once the transcript is processed.